Robert Millham

Author PubWeight™ 13.85^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.	J Clin Oncol	2005	4.77
2	Fit-for-purpose method development and validation for successful biomarker measurement.	Pharm Res	2006	2.96
3	Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.	Oncologist	2007	1.93
4	Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.	Clin Cancer Res	2011	1.66
5	Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR pathway.	Rev Recent Clin Trials	2010	1.02
6	Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy.	Clin Cancer Res	2007	0.92
7	Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.	Invest New Drugs	2014	0.89